Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (141-150 of 179) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast CancerJamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Breast Cancer Research and Treatment|November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2012
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelinesRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerCynthia X Ma, Ron Bose, Feng Gao, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 26, 2010
Breast cancer: noninvasive and special situationsRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 25, 2008
Non-Hodgkin's lymphomasAndrew D Zelenetz, Ranjana H Advani, John C Byrd, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2011
Invasive breast cancerRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2010
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomasAndrew D Zelenetz, Jeremy S Abramson, Ranjana H Advani, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Pageof 18

Showing results (141-150 of 179) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast CancerJamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Breast Cancer Research and Treatment|November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2012
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelinesRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerCynthia X Ma, Ron Bose, Feng Gao, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 26, 2010
Breast cancer: noninvasive and special situationsRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 25, 2008
Non-Hodgkin's lymphomasAndrew D Zelenetz, Ranjana H Advani, John C Byrd, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2011
Invasive breast cancerRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2010
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomasAndrew D Zelenetz, Jeremy S Abramson, Ranjana H Advani, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Pageof 18